Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Galcanezumab for Migraine
Recruiting2 awardsPhase 4
Santa Ana, California
This trial is comparing two medications, galcanezumab and rimegepant, to see which is better at preventing migraines in people who have them occasionally. Both medications work by blocking a protein that triggers migraine pain. The study will last several months. Galcanezumab has been shown to reduce migraine headache days in previous studies.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service